RhumbLine Advisers’s Akoya BioSciences AKYA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-10,700
| Closed | -$13.9K | – | 4121 |
|
|
2025
Q2 | $13.9K | Sell |
10,700
-63,555
| -86% | -$76.5K | ﹤0.01% | 3834 |
|
|
2025
Q1 | $103K | Buy |
74,255
+42,204
| +132% | +$92.4K | ﹤0.01% | 3380 |
|
|
2024
Q4 | $73.4K | Buy |
32,051
+1,590
| +5% | +$4.21K | ﹤0.01% | 3559 |
|
|
2024
Q3 | $82.8K | Buy |
30,461
+1,729
| +6% | +$4.22K | ﹤0.01% | 3560 |
|
|
2024
Q2 | $67.2K | Sell |
28,732
-5,125
| -15% | -$16.3K | ﹤0.01% | 3617 |
|
|
2024
Q1 | $159K | Buy |
33,857
+798
| +2% | +$4.14K | ﹤0.01% | 3279 |
|
|
2023
Q4 | $161K | Buy |
33,059
+9,012
| +37% | +$37.4K | ﹤0.01% | 3283 |
|
|
2023
Q3 | $112K | Buy |
24,047
+545
| +2% | +$3.13K | ﹤0.01% | 3426 |
|
|
2023
Q2 | $174K | Buy |
23,502
+3,887
| +20% | +$25.9K | ﹤0.01% | 3309 |
|
|
2023
Q1 | $160K | Buy |
19,615
+342
| +2% | +$3.57K | ﹤0.01% | 2786 |
|
|
2022
Q4 | $184K | Buy |
19,273
+829
| +4% | +$10.2K | ﹤0.01% | 2810 |
|
|
2022
Q3 | $217K | Buy |
18,444
+1,531
| +9% | +$20.2K | ﹤0.01% | 2866 |
|
|
2022
Q2 | $217K | Buy |
+16,913
| New | +$175K | ﹤0.01% | 2903 |
|
RhumbLine Advisers's AKYA Position: Q3 2025 in Review
RhumbLine Advisers sold out of Akoya BioSciences (AKYA) in Q3 2025, closing a stake of 10,700 shares — an estimated $13.9K sold.
RhumbLine Advisers first reported a position in AKYA in Q2 2022 and held it in 13 quarters. The position peaked at $217K in Q3 2022. 0 funds tracked by Wall St. Rank hold AKYA as of Q3 2025.
- RhumbLine Advisers reported no remaining Akoya BioSciences position as of Q3 2025 after selling out during the quarter.
- RhumbLine Advisers sold 10,700 Akoya BioSciences shares in Q3 2025, an estimated $13.9K.
- RhumbLine Advisers first reported a position in Akoya BioSciences in Q2 2022 and held it in 13 quarters.
- RhumbLine Advisers's Akoya BioSciences position peaked at $217K in Q3 2022.
- 0 funds tracked by Wall St. Rank held Akoya BioSciences as of Q3 2025.
Based on RhumbLine Advisers's 13F filing for Q3 2025, filed 6 Nov 2025.